

PRIVATE HEALTHCARE MARKET INVESTIGATION

Disclosure of interests

1. Roger Witcomb has appointed a Group of members to consider the above market investigation. The Group are [Roger Witcomb](#), [Jonathan Whiticar](#), [Jayne Almond](#), [Jeremy Peat](#) and [Tony Morris](#). Roger Witcomb will act as Chair of the Group.
2. This document discloses interests of Group members. This information supplements the information disclosed on their register of interests on the Competition Commission (CC) website. It also discloses interests of certain CC staff.
3. In addition to the matters below, the CC notes that members and staff working on this inquiry and close relatives of either may from time to time hold policies of private medical insurance or receive private medical treatment.

Members

4. Roger Witcomb has a close non-dependent relative who is an NHS hospital doctor but who is not a consultant.
5. Jonathan Whiticar has a shareholding valued at under £5,000 in Aviva plc and two close non-dependent relatives who are NHS hospital doctors, one of whom is a consultant.
6. Tony Morris has a holding of shares valued below £5,000 in Aviva plc.
7. There are no disclosures for Jeremy Peat or Jayne Almond.

Staff

8. Roland Green, the CC Chief Legal Adviser, is married to an NHS hospital doctor who also provides private healthcare services.
9. Carole Begent, Deputy Legal Adviser and Head of International, has a shareholding valued at under £5,000 in Aviva plc.
10. The CC does not consider that any of these matters will prejudice the ability of the CC to discharge its functions in an independent and impartial manner.
11. In accordance with our normal practice these matters will be disclosed on the CC's website.

23 July 2012

Update to staff disclosure

12. Kate Collyer has recently been appointed as an Economics Director at the CC. Her partner is an adviser to one of the parties to this inquiry. She will not be the Economics Director or a member of the case team responsible for advising members on this inquiry. However, as a member of the senior economics team at the CC with

sectoral experience, we expect her to have a limited review role in reviewing analytic approaches being followed.

13. The CC is satisfied that this will not prejudice the ability of the CC to discharge its functions in an independent and impartial manner.

14 December 2012

Update to disclosure notice

Notification of Dr Howard Smith's and Professor Alistair McGuire's assistance with the private healthcare market investigation

14. Dr Howard Smith, Lecturer in Economics at University of Oxford, has been asked to assist staff in their work on the private healthcare market investigation. Further information about Dr Smith can be found on his [website profile](#).
15. Dr Smith has a shareholding valued at under £5,000 in Aviva plc.
16. Professor Alistair McGuire, a Professor in Health Economics at London School of Economics, has been asked to assist staff in their work on the private healthcare market investigation. A full list of Professor McGuire's publications is available on his [website profile](#).
17. The CC does not consider that any of these matters will prejudice the ability of the CC to discharge its functions in an independent and impartial manner.

7 November 2013

Update to disclosure notice

18. Bertram Neurohr, an economic adviser, worked at Compass Lexecon (CL) from June 2010 to October 2013. Although the CC notes that CL advises a party to the inquiry, we are informed that while working for CL he had no involvement in its work on the inquiry or access to confidential information relating to the inquiry.
19. The CC does not believe that this matter will prejudice the ability of the CC to discharge its functions in an independent and impartial manner.

6 December 2013

Update to disclosure notice

20. Dr Pasquale Schiraldi, Lecturer at London School of Economics, has been asked to assist staff in their work on the private healthcare market investigation. Further information about Dr Schiraldi can be found on his [website profile](#).
21. Dr Schiraldi has a shareholding valued at under £1,000 in a fund that invests in healthcare, medical services and related products and companies worldwide.
22. The CC is satisfied that this will not prejudice the ability of the CC to discharge its functions in an independent and impartial manner.